Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma |
Kaya, Halide
(Department of Chest Diseases, Faculty of Medicine, Dicle University)
Demir, Melike (Department of Chest Diseases, Faculty of Medicine, Dicle University) Taylan, Mahsuk (Department of Chest Diseases, Faculty of Medicine, Dicle University) Sezgi, Cengizhan (Department of Chest Diseases, Faculty of Medicine, Dicle University) Tanrikulu, Abdullah Cetin (Department of Chest Diseases, Faculty of Medicine, Dicle University) Yilmaz, Sureyya (Department of Chest Diseases, Faculty of Medicine, Dicle University) Bayram, Mehmet (Department of Pulmonology, Faculty of Medicine, Bezmialem Vakif University) Kaplan, Ibrahim (Department of Medical Biochemistry, Faculty of Medicine, Dicle University) Senyigit, Abdurrahman (Department of Chest Diseases, Faculty of Medicine, Dicle University) |
1 | Hollevoet K, Reitsma JB, Creaney J, et al (2012). Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol, 30, 1541-9. DOI |
2 | Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS (2009). Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res, 7, 1756-70. DOI |
3 | Kim EJ, Lee SY, Woo MK, et al (2012). Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol, 40, 402-8. |
4 | Kim YJ, Yoon HY, Kim SK, et al (2011). EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res, 17, 4523-30. DOI |
5 | Komurcuoglu B, Cirak AK, Kirakli SC, et al (2014). Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects. Tumori, 100, 55-9. |
6 | Metintas M, Metintas S, Ucgun I, et al (2001). Prognostic factors in diffuse malignant pleural mesothelioma: pretreatment clinical and laboratory characteristics. Respir Med, 95, 829-35. DOI |
7 | Metintas M, Metintas S, Ak G, et al (2008). Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure. Respirology, 13, 117-21. DOI |
8 | Metintas S, Metintas M, Ucgun I, Oner U (2002). Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest, 122, 2224-9. DOI |
9 | Nojiri S, Gemba K, Aoe K, et al (2011). Survival and Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Study of 314 patients in the West Part of Japan. Jpn J Clin Oncol, 41, 32-9. DOI |
10 | Nomoto S, Kanda M, Okamura Y, et al (2010). Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol, 17, 923-32. DOI |
11 | O'Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R (2010). Elevated preoperative C- reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol, 5, 988-92. DOI |
12 | Ordonez NG (2003). The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol, 27, 1031-51. DOI |
13 | Pass HI, Levin SM, Harbut MR, et al (2012). Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med, 367, 1417-27. DOI |
14 | Pierce BL, Ballard-Barbash R, Bernstein L, et al (2009). Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol, 27, 3437-44. DOI ScienceOn |
15 | Rusch VW, Venkatraman ES (1999). Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg, 68, 1799-804. DOI |
16 | Senyigit A, Babayigit C, Gokirmak M, et al (2000). Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration, 67, 610-4. DOI |
17 | Tanrikulu AC, Abakay A, Kaplan MA, et al (2010). A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration, 80, 480-7. DOI |
18 | Van Gelder T, Damhuis RAM, Hoogsteden HC (1994). Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J, 7, 1035-38. |
19 | Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED (2008). US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev, 17, 525-34. DOI ScienceOn |
20 | Tong JD, Jiao NL, Wang YX, Zhang YW, Han F (2011). Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma, 58, 441-8. DOI |
21 | Vogelzang NJ, Rusthoven JJ, Symanowski J, et al (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21, 2636-44. DOI |
22 | Wang CS, Sun CF (2009). C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J, 32, 471-82. |
23 | Zhang Y, Marmorstein LY (2010). Focus on molecules: fibulin-3 (EFEMP1). Exp Eye Res, 90, 374-5. DOI |
24 | Boutin C, Rey F, Gouvernet J, et al (1993). Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer, 72, 394-404. DOI |
25 | Agha MA, El-Habashy MM, El-Shazly RA (2014). Role of fibulin-3 in the diagnosis of malignant mesothelioma. Egyptian J Chest Diseases Tuberculosis, 63, 99-105. DOI |
26 | Antman KH (1993). Natural history and epidemiology of malignant mesothelioma. Chest, 103, 373-6. DOI |
27 | Berk S, Dogan OT, Kilickap S, et al (2013). Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: Eighteen years' experience in Turkey. Asian Pac J Cancer Prev, 13, 5735-9. |
28 | Creaney J, Robinson BW (2009). Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med, 15, 366-70. DOI |
29 | Creaney J, Dick IM, Meniawy TM, et al (2014). Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax, 69, 895-902. DOI |
30 | Edwards JG, Abrams KR, Leverment JN, et al (2000). Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax, 55, 731-5. DOI |
31 | Hefler LA, Concin N, Hofstetter G, et al (2008). Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res, 14, 710-4. DOI |